VVOS
Vivos Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.19
+6.76%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 20.9M | 17.4M | 15.0M | 13.8M | 16.0M |
| Cost of Revenue | 8.4M | 6.9M | 6.0M | 5.5M | 6.0M |
| Gross Profit | 12.5M | 10.5M | 9.0M | 8.3M | 10.0M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 33.7M | 29.1M | 19.6M | 24.9M | 34.4M |
| General & Admin Expense | 32.5M | 27.7M | 17.9M | 22.5M | 29.0M |
| Selling & Marketing Expense | 1.2M | 1.4M | 1.7M | 2.5M | 5.3M |
| Other Expenses | 1.3M | 1.3M | 581.0K | 621.0K | 669.0K |
| Total Operating Expenses | 35.0M | 30.4M | 20.2M | 25.6M | 35.0M |
| Cost and Expenses | 43.5M | 37.3M | 26.2M | 31.1M | 41.1M |
| Operating Income (EBIT) | (22.6M) | (19.9M) | (11.2M) | (17.3M) | (25.0M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | 89.0K |
| Interest Expense | 1.1M | — | — | — | — |
| Net Interest Income | (1.1M) | — | — | — | 89.0K |
| Other Non-Op Income/Expense | (3.1M) | (1.3M) | 35.0K | 3.7M | 1.2M |
| Non-Operating Income (excl Interest) | 2.0M | 1.3M | (35.0K) | (3.7M) | (1.2M) |
| EBT (Pre-Tax Income) | (25.6M) | (21.2M) | (11.1M) | (13.6M) | (23.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (25.6M) | (21.2M) | (11.1M) | (13.6M) | (23.8M) |
| Earnings from Cont. Ops | (25.6M) | (21.2M) | (11.1M) | (13.6M) | (23.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (25.6M) | (21.2M) | (11.1M) | (13.6M) | (23.8M) |
| Per Share | |||||
| Basic EPS | ($2.06) | ($2.06) | ($2.22) | ($11.14) | ($25.90) |
| Diluted EPS | ($2.06) | ($2.06) | ($2.22) | ($11.14) | ($25.90) |
| Revenue Per Share | $1.18 | $1.70 | $2.99 | $11.32 | $17.41 |
| Shares | |||||
| Basic Shares Outstanding | 17.7M | 10.3M | 5.0M | 1.2M | 920484 |
| Diluted Shares Outstanding | 17.7M | 10.3M | 5.0M | 1.2M | 920484 |
| Profitability Metrics | |||||
| EBITDA | (23.2M) | (19.9M) | (10.6M) | (13.0M) | (23.2M) |
| D&A | 1.3M | 1.3M | 581.0K | 621.0K | 669.0K |
| EBIT | (24.5M) | (21.2M) | (11.1M) | (13.6M) | (23.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026